Server is temporarily unavailable
Main category: cholesterol
Also included in: clinical trials / drug trials;  Pharma Industry / biotech industry
Article date: 09 Sep 2011-2: 00 PDT window.fbAsyncInit = function() {FB.init({_appId:_'aa16a4bf93f23f07eb33109d5f1134d3',_status:_true,_cookie:_true,_xfbml:_true,_channelUrl:_'http://www.medicalnewstoday.com/scripts/facebooklike.html'});}; (function() {var s = document.createElement('script'); = true e.async; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e);}()); email to a friend printer friendly opinions

Spherix incorporated (NASDAQ: SPEX) at innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies announced that its drug candidate, SPX-106, achieved a statistically significant reductions in VLDL and LDL cholesterol when administered in combination with Dtagatose (SPX-106T) for nine weeks to genetically engineered mice prone to dyslipidemia. The aortas of these mice also showed reductions in the extent of atherosclerotic lesions as measured by lesion area in response to treatment. These lipoprotein analysis and lesion measurement results represent the final data from the study whose earlier triglycerides outcome which first announced on June 2, 2011.

Treatment of animals using a range of low doses of SPX-106T twice daily significantly reduced VLDL by 35% (from 127 mg / dl to 82 mg / dl) and LDL by 18% (from 141 to 116 mg / dl) (p = 0.05). Importantly, the same therapy so reduced atherosclerotic by area in the aortic arch to less than one - the value of the untreated group helped (graphic available at http://www.spherix.com/pdf/press/PRgraphic9-12-11.pdf). The aortic arch is generally the region where vessel disease first develops. In longer studies and in models in which high serum triglycerides fully develops, disease spreads in the vessel from the aortic arch to include the thoracic aorta. The study what not powered for an atherosclerosis endpoint and the aortas were obtained for post hoc analysis when the effectiveness of SPX-106T in lowering triglycerides and cholesterol became apparent.

Earlier this year Spherix initiated the preclinical development of SPX-106T as a treatment for hypertriglyceridemia in one arm of a study designed to evaluate both D-tagatose alone and the combination. The first studies designed specifically to test SPX-106T are nearing completion and results will be announced this fall. The company plans to start at initial human efficacy study in the first quarter of 2012. rapid progression to the clinic is made possible by the experienced team in place at the company.

"Having just successfully completed two global clinical trials for a diabetes indication, Spherix has the personnel to design and execute new dyslipidemia trials much faster than other companies of a similar size," notes Dr. Claire Kruger, CEO of Spherix. "The preclinical pipeline of our Biospherics subsidiary can be advanced to the clinical stage rapidly because the company is able to successfully execute multiple studies simultaneously."

Source: Spherix incorporated

Article adapted by medical news today from original press release.

Visit our cholesterol section for the latest news on this subject.

There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

APA
Spherix incorporated (2011, September 9). SPX-106T treatment yields significant reductions in serum VLDL and LDL cholesterol in mice. Medical news today. Retrieved September 9, 2011 from http://www.medicalnewstoday.com/releases/234136.php MLA
Spherix incorporated. "SPX 106T Treatment Yields Significant Reductions In Serum VLDL And LDL Cholesterol In Mice". Medical news today, September 9, 2011. Web. 9 Sep, 2011.

Please note: If no author information is provided, the source is cited instead.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact our news editor

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send press any medical news or health news releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Peliculas Online